What is Ultrasight?
Ultrasight operates within the health-tech sector, providing a sophisticated platform that integrates with handheld ultrasound devices. This technology facilitates cardiac sonography directly at the point of care, aiming to enhance the speed and accuracy of patient diagnoses and subsequent treatment. Based in Rehovot, Israel, the company's solution addresses a critical need for accessible and efficient diagnostic tools in healthcare settings, positioning it as a key player in the medical imaging and diagnostics market.
How much funding has Ultrasight raised?
Ultrasight has raised a total of $15M across 2 funding rounds:
Series A
$2M
Series B
$13M
Series A (2019): $2M with participation from Yozma Group
Series B (2021): $13M led by Atain Specialty Insurance Company, Yozma Group Korea, and Weizmann Institute of Science
Key Investors in Ultrasight
Weizmann Institute of Science
The Weizmann Institute of Science is a renowned research institution, suggesting a focus on cutting-edge, science-driven innovations and potentially early-stage ventures with strong academic backing.
Yozma Group
Yozma Group is a venture capital firm known for its investments in technology and innovation, likely providing strategic guidance and capital to fuel Ultrasight's growth and market penetration.
Atain Specialty Insurance Company
Undisclosed investor participating in the funding round.
What's next for Ultrasight?
The substantial enterprise-level funding Ultrasight has garnered, particularly the recent strategic investment, indicates a pivotal stage for the company. This capital infusion is likely earmarked for scaling operations, expanding market reach, and further developing its proprietary technology. Ultrasight is poised to solidify its position in the competitive health-tech landscape, potentially driving innovation in non-invasive cardiac diagnostics and improving patient outcomes globally.
See full Ultrasight company page
